Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 27:12:984896.
doi: 10.3389/fonc.2022.984896. eCollection 2022.

Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Yunkai Xie  1 , Weimin Kong  1 , Xiaoling Zhao  1 , He Zhang  1 , Dan Luo  1 , Shuning Chen  1
Affiliations
Review

Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Yunkai Xie et al. Front Oncol. .

Abstract

Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown encouraging efficacy in the treatment of cervical cancer. ICIs have been approved for use in both first- and second-line cervical cancer therapies. This review summarizes the current knowledge of ICIs and the application of ICIs in clinical trials for the treatment of cervical cancer.

Keywords: PD- 1/L1; cervical cancer; clinical trials; immune checkpoint inhibitors; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of action of ICIs in the anticancer immune response. Created with © BioRender.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Guimaraes YM, Godoy LR, Longatto-Filho A, Reis RD. Management of early-stage cervical cancer: A literature review. Cancers (Basel) (2022) 14:575. doi: 10.3390/cancers14030575 - DOI - PMC - PubMed
    1. Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, et al. . Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines. Obstet Gynecol (2019) 134:49–57. doi: 10.1097/AOG.0000000000003311 - DOI - PMC - PubMed
    1. NCCN . Clinical practice guidelines in oncology: Cervical cancer version 1.2022. Plymouth meeting. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.

LinkOut - more resources